Aadi Bioscience, Inc. (NASDAQ:AADI) Short Interest Update

Aadi Bioscience, Inc. (NASDAQ:AADI) saw a large increase in short interest in the month of September. As of September 15th, there was short interest totalling 394,100 shares, an increase of 22.8% from the August 31st total of 320,900 shares. Based on an average trading volume of 294,600 shares, the short-interest ratio is presently 1.3 days. Currently, 2.2% of the shares of the company are short sold.

Analysts Set New Price Targets

AADI has been the subject of several recent research reports. Jefferies Financial Group cut shares of Aadi Bioscience from a “buy” rating to a “hold” rating and cut their price objective for the company from $11.00 to $1.50 in a research report on Wednesday, August 21st. Piper Sandler downgraded shares of Aadi Bioscience from an “overweight” rating to a “neutral” rating and decreased their price objective for the stock from $5.00 to $1.75 in a research note on Tuesday, August 27th. HC Wainwright reaffirmed a “neutral” rating on shares of Aadi Bioscience in a research note on Wednesday, August 21st. TD Cowen lowered Aadi Bioscience from a “buy” rating to a “hold” rating in a research note on Wednesday, August 21st. Finally, Piper Sandler Companies downgraded Aadi Bioscience from an “overweight” rating to a “neutral” rating and set a $1.75 price objective on the stock. in a research report on Tuesday, August 27th. Five analysts have rated the stock with a hold rating, According to MarketBeat.com, Aadi Bioscience presently has a consensus rating of “Hold” and a consensus price target of $10.25.

Aadi Bioscience Stock Up 1.0 %

Shares of AADI stock opened at $1.93 on Monday. The company’s 50 day moving average is $1.66 and its 200 day moving average is $1.77. The firm has a market cap of $47.39 million, a price-to-earnings ratio of -0.76 and a beta of 0.69. Aadi Bioscience has a 52-week low of $1.21 and a 52-week high of $5.70.

Aadi Bioscience (NASDAQ:AADI) last posted its earnings results on Wednesday, August 7th. The company reported ($0.54) EPS for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.17. The company had revenue of $6.18 million during the quarter, compared to analysts’ expectations of $6.33 million. Aadi Bioscience had a negative net margin of 274.77% and a negative return on equity of 66.67%. During the same quarter in the prior year, the company posted ($0.67) earnings per share. Analysts anticipate that Aadi Bioscience will post -2.02 EPS for the current fiscal year.

Insiders Place Their Bets

In other Aadi Bioscience news, Chairman Neil Desai sold 40,000 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $1.71, for a total transaction of $68,400.00. Following the completion of the transaction, the chairman now owns 1,171,543 shares of the company’s stock, valued at approximately $2,003,338.53. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last 90 days, insiders have sold 61,067 shares of company stock worth $99,096. Company insiders own 37.30% of the company’s stock.

Institutional Trading of Aadi Bioscience

A number of institutional investors have recently bought and sold shares of AADI. Marquette Asset Management LLC purchased a new stake in Aadi Bioscience during the 1st quarter valued at about $135,000. Acuitas Investments LLC lifted its holdings in shares of Aadi Bioscience by 10.8% during the second quarter. Acuitas Investments LLC now owns 352,483 shares of the company’s stock worth $515,000 after purchasing an additional 34,344 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in Aadi Bioscience in the second quarter valued at approximately $37,000. 52.08% of the stock is currently owned by institutional investors and hedge funds.

Aadi Bioscience Company Profile

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.